Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Mycobacterium mucogenicum bacteremia in immune-compromised patients, 2008-2013. Diagn Microbiol Infect Dis 2016 Jun;85(2):182-5 PMID: 27117516

Pubmed ID

27117516

DOI

10.1016/j.diagmicrobio.2016.02.012

Abstract

Mycobacterium mucogenicum (MM) is a rapidly growing nontuberculous mycobacterium that may rarely cause bacteremia in immune-compromised hosts. All MM cases from 2008 to 2013 were analyzed across 4 risk groups: stem cell transplantation (SCT), hematologic malignancy, solid tumors, and others. Descriptive analysis was performed, as well as comparative analysis of neutropenic patients (absolute neutrophil count ≤1000/μL) with nonneutropenic patients. Of 39 MM cases, 27 patients had undergone SCT. Neutropenia was present in 12 patients. There was a significant difference in the presence of fever at the time of MM bacteremia between neutropenic and nonneutropenic groups (92% versus 42%; P=0.005). Central venous catheter (CVC) was present in 33 cases. All patients were treated with >1 antibiotic. Most frequently used combination antibiotic regimen involved clarithromycin and amikacin. Median duration of antibiotic treatment was 42days. Bacteremia resolved in all cases with CVC removal and combination antibiotic treatment.

Author List

Abidi MZ, Ledeboer N, Banerjee A, Hari P

Authors

Anjishnu Banerjee PhD Assistant Professor in the Institute for Health and Equity department at Medical College of Wisconsin
Parameswaran Hari MD Chief, Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-84964211718   1 Citations

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
Bacteremia
Humans
Immunocompromised Host
Male
Middle Aged
Mycobacterium Infections, Nontuberculous
Retrospective Studies
Risk Factors
Treatment Outcome
Young Adult
jenkins-FCD Prod-332 f92a19b0ec5e8e1eff783fac390ec127e367c2b5